News | Robotic Systems | April 24, 2017

Clinical Study Validates Efficiencies of Stereotaxis Niobe ES System Over Niobe II System

Study of 184 patients compared latest-generation remote magnetic navigation system to previous generation in terms of procedure and fluoroscopy times for atrial fibrillation ablation procedures

Clinical Study Validates Efficiencies of Stereotaxis Niobe ES System Over Niobe II System

April 24, 2017 — A recent study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France validated the advantages of the Niobe ES magnetic navigation system over the Niobe II system in terms of procedure and fluoroscopy times for atrial fibrillation (AF) ablation procedures. The study was published in the International Journal of Cardiology and represents the first comparison study of Stereotaxis’ latest-generation remote magnetic navigation system to its predecessor.

“Our aim with this study was to quantify the clinical improvements that we have experienced with complex arrhythmia ablations, specifically AF, since upgrading to the Niobe ES system,” said Antoine Da Costa, M.D., Ph.D., chief of the EP (electrophysiology) Unit at CHU of Saint-Étienne. “We sought to evaluate procedure duration, as well as efficacy and extent of fluoroscopic exposure associated with the Niobe ES system compared to the Niobe II in patients requiring AF ablation. Our results confirmed that the Niobe ES system reduced procedure time and X-ray exposure by a minimum of 30 percent, primarily due to the system’s enhanced responsiveness.” 

In the Saint-Étienne study, researchers compared data on 92 consecutive patients treated with the Niobe ES system to 92 consecutive patients treated using the Niobe II system for symptomatic drug-refractory atrial fibrillation. The percentage of circumferential pulmonary vein isolation, as confirmed via spiral catheter recording during ablation, was 100 percent. Procedure time was significantly lower with the Niobe ES system than the Niobe II system (1.9 ± 0.4 vs. 2.7 ± 1h, p < 0.0001), as was X-ray duration (12 ± 4 vs. 15 ± 7 min, p = 0.001).

The EP Unit at CHU of Saint-Étienne first implemented Stereotaxis technology in 2009 and installed a second Niobe system in 2015. They are recognized as a national center of excellence, consistently ranked in the top five for interventional cardiology in France, as well as a European center of reference in the treatment of complex arrhythmias. 

The Niobe ES system constitutes Stereotaxis’ fourth-generation magnetic navigation technology, designed to improve functionality through faster computing hardware, new motion controllers and a more intuitive user interface. By creating a near real-time response to catheter movement commands, the Niobe ES enables an operator to navigate an ablation catheter more quickly, precisely and with little fluoroscopic guidance. The ensuing results can be faster anatomy-specific ablation procedures with significantly less X-ray exposure to the patient and physician.

For more information: www.stereotaxis.com 


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now